Revenue
No reported data
Acumen Pharmaceuticals, Inc. (ABOS)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $104.9M | $93.8M | $42.3M | $32.4M | $12.3M | $8.0M |
| Operating expenses | $123.8M | $114.0M | $61.1M | $45.2M | $19.6M | $9.3M |
| Operating income | −$123.8M | −$114.0M | −$61.1M | −$45.2M | −$19.6M | −$7.9M |
| Net income | −$121.3M | −$102.3M | −$52.4M | −$42.9M | −$100.6M | −$7.3M |
| Basic EPSper diluted share | -$2.00 | -$1.71 | -$1.08 | -$1.06 | -$5.02 | -$17.48 |
| Diluted EPSper diluted share | -$2.00 | -$1.71 | -$1.08 | -$1.06 | -$5.02 | -$17.48 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 17, 2026Form 4 | Porter DerrellDirector | SellCommon Stock | 13.0K | $2.33 | $30.4K | 35.5K |
| Jun 16, 2026Form 4 | Porter DerrellDirector | SellCommon Stock | 12.8K | $2.33 | $29.8K | 35.5K |
| Jun 15, 2026Form 4 | Porter DerrellDirector | SellCommon Stock | 6.5K | $2.35 | $15.2K | 48.3K |
| Jun 9, 2026Form 4 | Fountain Nathan BDirector | SellCommon Stock | 6.4K | $2.23 | $14.3K | 48.1K |
| Mar 6, 2026Form 4 · 10b5-1 | Meisner Derek MChief Legal Officer & Corp Sec | SellCommon Stock | 2.1K | $3.26 | $6.8K | 174.0K |